Cytomegalovirus retinitis.
Aniki
A
Rothova
Okke
O
de Weerdt
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects*; D000914:Antibodies, Viral / Q000097:blood; D001082:Aqueous Humor / Q000821:virology; D003587:Cytomegalovirus / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification; D017726:Cytomegalovirus Retinitis / Q000188:drug therapy / Q000209:etiology*; D004359:Drug Therapy, Combination; D017245:Foscarnet / Q000627:therapeutic use; D015774:Ganciclovir / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016399:Lymphoma, T-Cell / Q000150:complications / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000188:drug therapy / Q000209:etiology*; D016133:Polymerase Chain Reaction; D019172:Transplantation Conditioning / Q000009:adverse effects*; D014184:Transplantation, Homologous; D014792:Visual Acuity; D014822:Vitreous Body / Q000821:virology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000914:Antibodies, Viral; D017245:Foscarnet; D000074323:Alemtuzumab; D015774:Ganciclovir